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BY-NC-ND license (http://creativecomAbstract Background: Pediatric patients under treatment for acute myeloid leukemia (AML)
are at high risk for invasive fungal infection (IFI). We evaluated the efficacy of prophylactic
administration of voriconazole (VRCZ) with two different doses.
Methods: Between October 2005 and June 2011, 17 children and adolescents (aged 0e20
years) undergoing chemotherapy for AML were prophylactically administered with 5 mg/
kg/d of oral VRCZ. Furthermore, 22 AML patients (aged 0e19 years) were administered
10 mg/kg/d of oral VRCZ between July 2011 and December 2014. The incidences of IFI with
two different doses of VRCZ were compared.
Results: Irrespective of the dosage of VRCZ, eight patients developed IFI. Of these eight pa-
tients, four belonged to the 5 mg/kg/d group and four to the 10 mg/kg/d group. Cumulative
incidences of IFI at 180 days after the initiation of chemotherapy were not different between
the 5 mg/kg/d and 10 mg/kg/d groups. The trough plasma VRCZ concentration in the 10 mg/
kg/d group ranged from < 0.09 mg/mL to 2.17 mg/mL, with a median level of 0.27 mg/mL, and
patients with the targeted trough concentration (1e4 mg/mL) comprised only 18.8% of the eva-
luable patients in this group, whereas the trough plasma VRCZ concentration of the evaluable
patients in the 5 mg/kg/d group were all below the limit of sensitivity (< 0.09 mg/mL).
Conclusion: More dose escalation is required based on this study. As VRCZ concentration is
considerably influenced by genetic polymorphisms and drugedrug interactions, VRCZ should
be used under therapeutic drug monitoring to keep effective drug concentrations.
Copyright ª 2016, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
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+ MODELIntroduction
Recent developments of therapies including chemo-
therapy and hematopoietic stem cell transplantation
(HSCT) have improved the survival of pediatric patients
with hematologic and malignant disorders. Nonetheless,
with intensification of therapy, such as multidrug chemo-
therapy and HSCT, there have been growing numbers of
severe infections including invasive fungal infection (IFI).
Patients with acute myeloid leukemia (AML) have been
shown to be at high risk of IFI,1e3 particularly invasive
Aspergillus spp. infection (IA),4 because of the intense
myelosuppressive and immunosuppressive effects of their
chemotherapeutic regimens. As the timely and accurate
diagnosis of IFI during the course of chemotherapy is
difficult, and because once it develops it is difficult to
treat, prophylactic antifungal administration is important
for high-risk patients.
Fluconazole has been widely used as the antifungal
prophylaxis in cancer patients5e8; however, it has no effect
on IA, Candida krusei, and other molds.5,9,10 Voriconazole
(VRCZ), a second-generation triazole, is effective against
Aspergillus spp., and it has also been shown to be effective
against other fungal pathogens, including some Candida
strains intrinsically resistant to fluconazole. By contrast,
compared with fluconazole, VRCZ may have greater
toxicities11e13 and drug interactions.14,15 There have been a
few trials concerning prophylactic administration of VRCZ
for pediatric acute leukemia16e18; however, its effective-
ness has not been well evaluated. Thus, we analyzed the
efficacy of prophylactic VRCZ administration in pediatric
patients with AML. We retrospectively compared the effi-
cacy between VRCZ at a dose of 5 mg/kg/d and 10 mg/kg/
d for the prevention of IFI.Methods
Patients
A total of 39 consecutive patients with AML who underwent
chemotherapy at Sapporo Hokuyu Hospital, Sapporo, Japan
between October 2005 and March 2015 were enrolled in this
study (every newly diagnosed or relapse-confirmed patient
with AML in this period was enrolled). The patients were
divided into two groups. Seventeen patients (9 boys and 8
girls, whose ages ranged from 0 years to 20 years, with a
median age of 7 years) hospitalized between October 2005
and June 2011 were prophylactically administered with
5 mg/kg/d in two divided doses (maximal dose, 200 mg/d)
of oral VRCZ starting at the beginning of chemotherapy. By
contrast, 22 patients (10 boys and 12 girls, age range, 0e19
years, median age, 10 years) hospitalized between July
2011 and March 2015 were prophylactically administered
with 10 mg/kg/d in two divided doses (maximal dose,
400 mg/d) of oral VRCZ.
Informed consent was obtained from the patients and/or
their parents, according to guidelines based on the tenets
of the revised Helsinki protocol. The Institutional Review
Board of Sapporo Hokuyu Hospital approved this study.Please cite this article in press as: Sano H, et al., Prophylactic adminis
infection in children and adolescents with acute myeloid leukemia, J
dx.doi.org/10.1016/j.jmii.2016.05.002Definitions of fever, neutropenia
Fever was defined as an axillary temperature of  37.5C
on two occasions at least 1 hour apart or a single axillary
temperature  38.0C. Neutropenia was defined as an ab-
solute neutrophil count of < 0.5  109/L.
Infection prophylaxis, and treatment strategy
against febrile neutropenia
All eligible patients were hospitalized in clean rooms of
NASA class 10,000. Trimethoprim-sulfamethoxazole was
prescribed to all patients for the prevention of Pneumo-
cystis jirovecii pneumonia. The prophylactic administration
of oral VRCZ at 5 mg/kg/d or 10 mg/kg/d was given as
described above. Prophylactic administrations of antibac-
terial agents were not routinely performed. No construc-
tion work was performed in the ward during the study
period.
When patients developed fever during neutropenia, the
following laboratory tests were performed: complete blood
cell count, peripheral blood smear, quantitative C-reactive
protein (CRP), liver and renal function, urinalysis, and
blood cultures from specimens obtained via peripheral
venous puncture and/or a central venous catheter, if in
place. Antibiotic therapy was begun as soon as possible
without waiting for the blood culture results. The initial
antibacterial drugs at the onset of fever were as follows:
ceftazidime (CAZ) plus piperacillin/tazobactum (PIPC/TAZ)
or sulbactam/ampicillin (SBT/ABPC) plus aztreonam (AZT)
from June 1, 2004 to March 31, 200619; CAZ plus PIPC/TAZ
or cefozopran (CZOP) monotherapy from April 1, 2006 to
March 31, 200820; CZOP monotherapy or cefepime (CFPM)
monotherapy from April 1, 2008 to March 31, 201021; PIPC/
TAZ monotherapy or CFPM monotherapy from April 1, 2010
to March 31, 201222; and PIPC/TAZ monotherapy or mer-
openem monotherapy from April 1, 2012 to March 31, 2015
(data not published).
Initial antibiotics were continued when a case of fever
was alleviated following initiation of antibiotics. In a case
of fever continuing following initiation of antibiotics, or
once resolved-fever and infectious signs subsequently
recurring in spite of the continuation of the same antibiotic
therapy, the laboratory tests including blood culture were
performed again, and the antimicrobial therapy was
changed to alternative antibacterial drugs or antifungal
drugs.
Identification and definition of IFI
For prompt intervention against fungal infection, patients’
blood samples were assayed for serum CRP by enzyme-
linked immunoassay at least twice a week. When fever
continued despite administration of broad-spectrum anti-
biotics and/or a high level of CRP persisted, computed to-
mography of the chest and abdomen was performed. In
these patients, the detection of serum b-D-glucan and
Aspergillus galactomannan antigen was also carried out.
IFI was defined and classified according to the stan-
dardized definitions from the European Organization fortration of voriconazole with two different doses for invasive fungal
ournal of Microbiology, Immunology and Infection (2016), http://
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fections Cooperative Group and the National Institute of
Allergy and Infectious Disease Mycosis Study Group (EORTC/
MSG) Consensus Group.23 Proven IFI was diagnosed by a
positive fungal culture from a normally sterile site. Prob-
able IFI was diagnosed on the basis of a combination of host
factors, clinical and radiological features, and mycological
evidence, such as positive fungal culture or microscopy of
bronchoalveolar lavage fluid or sinus aspirate. Possible IFI
was diagnosed when the clinical and imaging findings, and
host factors were consistent with IFI but there was no
mycological evidence.Analytic procedures
The primary hypothesis was whether VRCZ prophylaxis at
10 mg/kg/d would be associated with lower cumulative
incidence of IFI after the initiation of chemotherapy for
AML compared to that with 5 mg/kg/d. The incidences of
proven, probable, or possible IFI during AML treatment
were compared between two groups classified by VRCZ
doses (5 mg/kg/d vs. 10 mg/kg/d). To evaluate the back-
ground of the enrolled patients, sex, age at hospitalization,
cell morphology based on the FrencheAmericaneBritish
classification, and duration of VRCZ administration were
also compared between the two groups. Trough plasma
VRCZ concentration was not monitored routinely; however,
it was evaluated in 22 out of 39 cases (6 of 17 cases in the
5 mg/kg/d group, and 16 of 22 cases in the 10 mg/kg/
d group). Trough plasma VRCZ concentration was evaluatedTable 1 Eight patients who developed IFI despite voriconazole
Pt Age
(y)
Sex FAB Dosing
period
(d)
Preceding
chemotherapy
IFI
(EORTC/
MSG)
Lesi
(org
1 16 M M7
(relapse)
219 ECM, GO,
FLAG,
BHAC-AMP
Possible Lun
2 7 F M2 118 ECM, HCEI,
HCM, HCEI
Proven Lun
brai
3 11 M M4Eo 32 ECM Possible Lun
4 4 F M7
(relapse)
28 FLAG Probable Lun
5 11 F M4 18 ECM Probable Lun
6 12 F M4
(relapse)
71 FLAGeIDA,
FLAGeIDA
Possible Lun
7 9 M M2
(relapse)
118 ECM, HCEI,
IDAeFLAG
Probable Lun
brai
8 17 M M2 158 ECM, HCEI,
HCM, HCEI
Possible Lun
AML Z acute myeloid leukemia; BHAC-AMP Z behenoyl cytarabine þ
posideþcytarabineþmitoxantrone; EORTC/MSG Z European Organiza
F Z female; FAB Z FrencheAmericaneBritish classification; FLAG
gND Z genus not defined; GO Z gemtuzumab ozogamicin; HCEI Z h
cytarabine þ mitoxantrone; HSCT Z hematopoietic stem cell tran
M Z male; NA Z not analyzed; PtZ patient; VRCZZ voriconazole.
Please cite this article in press as: Sano H, et al., Prophylactic administ
infection in children and adolescents with acute myeloid leukemia, J
dx.doi.org/10.1016/j.jmii.2016.05.002at least 7 days after initiation of VRCZ. Data were analyzed
as of August 1, 2015.
Statistical analysis
A c2 test or ManneWhitney U test was used to compare pa-
tients between the two groups. Cumulative incidence of IFI
was assessed using the KaplaneMeier method. Cumulative
incidence of IFI, incorporating death as a competing risk,was
computed for time from the initiation of chemotherapy to
IFI. The Gray test was used to compare the two treatment
arms. All statistical analyses were performed with EZR (Sai-
tama Medical Center, Jichi Medical University, Saitama,
Japan), which is a graphical user interface for R (The R
Foundation for Statistical Computing, Vienna, Austria). More
precisely, it is a modified version of the R commander
designed to add statistical functions frequently used in
biostatistics.24
Results
Clinical characteristics
Irrespective of the prophylactic dosage of VRCZ, eight of 39
enrolled patients developed IFI (proven 1, probable 3,
possible 4; Table 1). Of these eight patients, four belonged
to the 5 mg/kg/d group and four to the 10 mg/kg/d group.
Among them, Aspergillus sp. was the pathogen of IFI in two
patients, one in the 5 mg/kg/d group, and one in the
10 mg/kg/d group. Mucor as the pathogen was found (1prophylaxis
on
an)
Predicted
pathogen
VRCZ dose
(mg/kg)
VRCZ
concentration
(mg/mL)
Outcome
(cause of
death)
g gND 5 NA Death
(AML/IFI)
g,
n
Mucor 5 NA Survival
g gND 5 NA Survival
g Aspergillus 5 NA Death
(AML/IFI)
g Aspergillus 10 0.24 Death
(AML/IFI)
g gND 10 NA Death
(AML/IFI)
g,
n
Mucor 10 NA Death
(AML/IFI)
g gND 10 0.21 Death
(complication
of HSCT)
aclacinomycin þ 6-mercaptopurine þ prednisolone; ECM Z eto-
tion for Research and Treatment of Cancer/Mycosis Study Group;
Z fludarabine þ AraC þ granulocyte colony stimulating factor;
igh dose-cytarabine þ etoposide þ idarubicin; HCM Z high-dose
splantation; IDA Z idarubicin; IFI Z invasive fungal infection;
ration of voriconazole with two different doses for invasive fungal
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patients, each belonging to one of the groups. In the
remaining four patients, genus of fungus could not be
identified. Concerning the clinical characteristics, including
age at diagnosis, sex, FrencheAmericaneBritish classifica-
tion, duration of VRCZ administration, and the reasons for
discontinuation of VRCZ, there were no differences be-
tween the two groups (Table 2).
Comparison of antifungal effects
In terms of breakthrough infection rate, there were no
differences between the two groups both in terms of the
number of patient-based analysis [5 vs. 10 mg/kg/d,
23.5% (4/17) vs. 18.2% (4/22), pZ 0.709] and theTable 2 Comparison of characteristics between patients
administered with 5 mg/kg/d and 10 mg/kg/d of
voriconazole
VRCZ dose 5 mg/kg/d 10 mg/kg/d p
No. of cases 17 22
No. of courses
of chemotherapy
55 79
Age (y) 0e20 0e19 0.504
(median) 7 10
Sex (male/female) 8/7 9/11 0.738
FAB classification 0.403
M1 3 (17.6) 1 (4.5) 0.300
M2 4 (23.5) 10 (45.5) 0.193
M4 1 (5.9) 4 (18.2) 0.363
M5 1 (5.9) 1 (4.5) 1.000
M6/RAEB 1 (5.9) 0 0.436
M7 6 (35.3) 5 (22.7) 0.482
(M7 with Down
syndrome)
(0) 3 (13.6) (0.243)
AML with MLD 1 (5.9) 1 (4.5) 1.000
Relapse of underlying
disease
2 (11.8) 2 (9.1) 1.000
Dosing period (d) 10e230 3e233 0.802
(median) 126 158
Reason for discontinuation
of VRCZ
0.071
Completion of
chemotherapy (AML)
4 (23.5) 9 (40.9) 0.318
Transition to HSCT 6 (35.3) 3 (13.6) 0.282
Febrile neutropenia
(change to other drug)
2 (11.8) 0 0.436
Development of IFI 4 (23.5) 4 (18.2) 0.709
Death due to AML 1 (5.9) 1 (4.5) 1.000
Going on VRCZ 0 5 (22.7) 0.118
VRCZ concentration
(mg/mL)
<0.09 <0.09e2.17 0.003
(median) <0.09 0.27
Data are presented as n (%), unless otherwise indicated.
AMLZ acute myeloid leukemia; FAB classificationZ
FrencheAmericaneBritish classification; HSCTZ hemato-
poietic stem cell transplantation; IFI Z invasive fungal infec-
tion; MLDZmultilineage dysplasia; RAEB Z refractory anemia
with excess blasts; VRCZZ voriconazole.
Please cite this article in press as: Sano H, et al., Prophylactic adminis
infection in children and adolescents with acute myeloid leukemia, J
dx.doi.org/10.1016/j.jmii.2016.05.002number of courses of chemotherapy-based analysis [7.3%
(4/55) vs. 4.8% (4/84), pZ 0.712]. The cumulative inci-
dence of IFI at 180 days after the initiation of chemo-
therapy was similar between the 5 mg/kg/d (22.0%; 95%
confidence interval, 0.0e41.4%) and 10 mg/kg/d (21.7%;
95% confidence interval, 0.0e8.7%) groups (pZ 0.552;
Figure 1).
Difference in concentration level of VRCZ
The trough plasma VRCZ concentration in the 10 mg/kg/
d group ranged from < 0.09 mg/mL to 2.17 mg/mL, with a
median concentration of 0.27 mg/mL, and patients with the
targeted trough plasma concentration (1e4 mg/mL)
constituted only 18.8% of the evaluable patients, whereas
the trough plasma VRCZ concentration of the evaluable
patients in the 5 mg/kg/d group were all below the limit of
sensitivity (< 0.09 mg/mL; Figure 2 and Table 2). Trough
plasma VRCZ concentrations in two patients who developed
IFI despite prophylactic administration at a dose of 10 mg/
kg/d were low (0.21 mg/mL and 0.24 mg/mL; Figure 2). The
trough plasma concentrations of the remaining six patients
with IFI (4 patients in the 5 mg/kg/d group and 2 patients in
the 10 mg/kg/d group) were not evaluated.
Adverse events in VRCZ prophylaxis
In both groups, there were no cases that required discon-
tinuation of VRCZ because of adverse effects. No patients
exhibited visual disturbances as an adverse effect of VRCZ.
Outcome following development of IFI
Among the eight patients who developed IFI, six patients
died. In five of six patients (Nos. 1 and 4e7), treatments for
underlying disease were postponed to resume and/or
treatment intensity was reduced for fear of exacerbation of
IFI under severe myelosuppression, which might lead to
relapse or failure to achieve remission of underlying dis-
ease. Then, IFI rapidly increased possibly because of lack ofFigure 1. Cumulative incidence of invasive fungal infection
in 39 cases with acute myeloid leukemia (AML). KaplaneMeier
estimates for patients treated with voriconazole at a dose of
5 mg/kg/d and 10 mg/kg/d are shown.
tration of voriconazole with two different doses for invasive fungal
ournal of Microbiology, Immunology and Infection (2016), http://
Figure 2. Distribution of plasma voriconazole concentration.
Six of 17 cases treated with voriconazole (VRCZ) at a dose of
5 mg/kg and 16 of 22 cases treated with VRCZ at a dose of
10 mg/kg/d are analyzed for trough concentration of VRCZ.
Closed circles with arrows represent two patients who devel-
oped invasive fungal infection (IFI) despite prophylactic use at
a dose of 10 mg/kg/d. A broken line indicates the lower limit of
the targeted VRCZ concentration.
VRCZ prophylaxis for pediatric patients with AML 5
+ MODELantifungal immunity, leading to death. The remaining pa-
tient (No. 8) had once recovered from IFI, but died of
complication of HSCT (Table 1).Discussion
IFI is one of the most life-threatening complications in
children and adolescents with hematologic and malignant
diseases, especially AML.1e4 Patients with IFI require anti-
fungal agents, and sometimes chemotherapy is reduced to
conserve their antifungal immunity for weeks to months,
which may lead to the relapse of the original disease.25
Moreover, the costs of prophylactic treatment were re-
ported to be significantly lower than those for treatment of
overt IFI.18 Thus, prophylaxis for IFI in such high-risk pa-
tients is important.
VRCZ is an effective prophylactic agent in adult patients
with AML26,27; however, only a few reports have been
published regarding the prophylactic use of VRCZ for pe-
diatric and adolescent AML patients.16e18 These reports
showed conflicting results. Maron et al17 compared the
frequency and outcome of invasive mold infection in AML
patients prior to and after implementation of VRCZ pro-
phylaxis, and concluded that VRCZ prophylaxis did not
reduce invasive mold infections. By contrast, Yeh et al18
reported a significant reduction of IFI in children with
AML by comparing patients prior to and after the intro-
duction of VRCZ prophylaxis.
One possible explanation for this difference in efficacy is
the difference in the dosage of VRCZ. The VRCZ dose in the
former report was 400 mg/d for patients weighing  40 kg,
and 200 mg/d for those weighing < 40 kg, whereas that of
the latter report was 8 mg/kg/d. As a result, patients
weighing 25e40 kg, and  50 kg in the former report
received a lower dose of VRCZ than patients in the latterPlease cite this article in press as: Sano H, et al., Prophylactic administ
infection in children and adolescents with acute myeloid leukemia, J
dx.doi.org/10.1016/j.jmii.2016.05.002report. Although age distribution of the patients who
developed IFI was not indicated in these studies, it is
possible that lower doses of VRCZ in patients weighing
25e40 kg and  50 kg might lead to insufficient efficacy in
prophylaxis of IFI. We used VRCZ at a dose of 5 mg/kg/
d from October 2005 to June 2011, but we increased the
VRCZ dose to 10 mg/kg/d starting in July 2011 and
continued this strategy until March 2015. Thus, we exam-
ined if VRCZ at a dose of 10 mg/kg/d was superior to that of
5 mg/kg/d in preventing AML patients from developing IFI.
However, there were no differences in cumulative inci-
dence of IFI at 180 days after the initiation of chemo-
therapy for AML between patients receiving prophylactic
VRCZ at a dose of 5 mg/kg/d and 10 mg/kg/d. The fre-
quency of IFI in pediatric patients with AML has been re-
ported to be 10e27%.3,28 This wide range ensues because it
tends to be influenced by various factors, such as environ-
ment of treatment/care, presence of construction work,
diagnostic capability in each hospital, preceding chemo-
therapy, or antifungal prophylaxis. Although we cannot
readily compare frequencies between different in-
stitutions, the frequencies of IFI in this study (23.5% in the
5 mg/kg/d group and 18.2% in the 10 mg/kg/d group) were
considered acceptable.
An unexpected finding in this study was that the trough
concentration of VRCZ was inadequately low even in pa-
tients with VRCZ at 10 mg/kg/d. Patients administered with
5 mg/kg/d so far all showed values below the limit of
sensitivity. The pharmacokinetics of VRCZ has not been
fully established, especially in the pediatric population. In
children between the ages of 2 years and 12 years, the
optimal dose may be 7 mg/kg twice daily,29,30 whereas in
children younger than 2 years, it may be as high as 8.5 mg/
kg/dose twice daily.31 Another report proposed a mainte-
nance dose of 8 mg/kg twice daily for all children younger
than 12 years, and for those 12e14 years of age weighing <
50 kg.32 At present, there is no consensus regarding the
appropriate dose of VRCZ. Nevertheless, it is possible that
the dose of 5 mg/kg/d or 10 mg/kg/d used in this study was
not sufficiently effective against fungal infection. No
adverse events concerning prophylactic use of VRCZ in this
study could be explained by lower plasma VRCZ concen-
tration. However, with regard to VRCZ dosage, there has
been one interesting report that showed no advantage of
14 mg/kg/d over 10 mg/kg/d in prophylaxis efficacy and
safety in children undergoing allogeneic HSCT.33 VRCZ also
has drugedrug interaction with many agents used in clinical
practice, because it is a substrate of CYP2CP, 2C19, 3A4,
and an inhibitor of 2C9, 2C19, 3A4.34 For these reasons,
therapeutic drug monitoring (TDM) is strongly recom-
mended in clinical practice31 to determine the optimal
plasma VRCZ concentration.
The limitations of this study include its retrospective
design, the small number of enrolled patients, and the fact
that it is a single-institution study. Another is the fact that
TDM of VRCZ was not routinely performed during the study
period (especially low numbers of cases in patients with
IFI), and polymorphisms that could influence plasma VRCZ
concentration were not checked in this study. In addition,
the concern about the existence of confounding factors
caused by using historical control could not be eliminated.
Nevertheless, the present study may provide valuableration of voriconazole with two different doses for invasive fungal
ournal of Microbiology, Immunology and Infection (2016), http://
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concentrations in the prophylaxis of IFI.
In conclusion, no differences were observed between
prophylactic VRCZ at 5 mg/kg/d and 10 mg/kg/d in the
frequency of IFI. Lower plasma VRCZ concentrations even
at the increased dosage may explain the lack of differences
in IFI prophylaxis in the present study. When taking into
consideration the antifungal spectrums of VRCZ, the pro-
phylactic use of it is expected for the prevention of IFI in
patients with AML, because they are at very high risk not
only for candidiasis but also for mold infections, especially
for IA. However, regarding dosage used for IFI prophylaxis,
more dose escalation is required based on this study.
Because VRCZ concentration is considerably influenced by
genetic polymorphisms and drugedrug interactions, VRCZ
prophylaxis should be done under TDM to maintain the
effective and safe drug concentration. This strategy might
be able to improve the risk of IFI in patients with AML.Conflicts of interest
The authors have no conflicts of interest to declare.References
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